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Summary The pharmacokinetic behaviour and phototherapeutic effectiveness of bis(di-isobutyloctadecylsil-
oxy)-2,3-naphthalocyanatosilicon (iso-BOSiNc) incorporated into dipalmitoyl-phosphatidylcholine (DPPC)
liposomes have been studied in Balb/c mice bearing an MS-2 fibrosarcoma. We found that iso-BOSiNc i.v. -
injected at a dose of 0.5 mg kg-' b.w. is preferentially transported by serum lipoproteins; in particular, the
photosensitiser is associated with LDL (57.8% of total recovery in the serum) and HDL (35.7%) while minor
amounts are associated to VLDL (2.63%) and other serum proteins (3.89%), Iso-BOSiNc concentrations
greater than 1 gig g-' of tissue are recovered from the tumour at 12-48 h after administration while the ratio
of iso-BOSiNc concentration in tumour and peritumoral tissue is greater than 10. Upon increasing the injected
dose, the additional iso-BOSiNc is almost exclusively bound by HDL, which leads to large uptake of the
photosensitiser by liver and spleen. The efficiency of iso-BOSiNc as a photodynamic agent was measured upon
irradiation with a different dose-rate for a total light dose of 450 J cm-2. The extent of tumour necrotic area
increases as a function of the time after the end of PDT treatment and reaches a maximum level after about
24 h. Moreover, the necrotic area is linearly dependent on the irradiation dose-rate up to 100 mW cm-2. In all
there is substantial evidence that iso-BOSiNc delivered in a liposomal dispersion is a highly effective
photosensitizer for PDT of tumours.
Photodynamic therapy (PDT) is a method of cancer treat-
ment, based on photosensitisation of the tumour to selected
wavelengths of visible light by phototherapeutic agents (Wil-
son & Jeeves, 1987). At present PDT is applied at the clinical
level using haematoporphyrin-IX (Hp-IX) (Tomio et al.,
1984) and haematoporphyrin derivative (HpD) (Dougherty,
1987) as photodynamic agents. However, Hp and HpD show
a small efficiency of red light absorption; moreover, HpD is a
highly heterogeneous mixture of porphyrins, while the
clinically used Hp contains about 15% porphyrin-type
impurities (Jori et al., 1983).
Other classes of photosensitisers, such as phthalocyanines
and chlorins, are provided with better red light-absorbing
properties than Hp: their absorption maxima are located
around 670 nm with extinction coefficients about
105 M-l cm-'; moreover, they are usually characterised by a
good degree of purity (Zhou, 1989). Recently, naph-
thalocyanines have been proposed as PDT agents (Firey &
Rodgers, 1987), since these compounds show intense absorp-
tion (a> IO M-l cm-') around 780 nm, namely in a spectral
interval where light penetration through the skin is approxi-
mately twice that at 630 nm (Wilson & Jeeves, 1987).
In this work we have studied the pharmacokinetic and
phototherapeutic properties of bis(di-isobutyloctadecylsiloxy)
-2,3-naphthalocyanato silicon (iso-BOSiNc) in mice bearing a
transplanted tumour. Flash photolysis studies (Firey &
Rodgers, 1987; Ford et al., 1988) have shown that iso-
BOSiNc triplet state has a long natural lifetime (331 jis) and
is produced with a quantum yield of 0.2. In oxygen-saturated
solutions of iso-BOSiNc in benzene the quantum yield of
singlet oxygen generation is 0.2; it is likely that this activated
derivative of oxygen plays a major role in photoinduced
necrosis of tumours (Moan, 1986).
Materials and methods
Chemicals
Bis(di-isobutyloctadecylsiloxy)-2,3-naphthalocyanato silicon
(iso-BOSiNc) was prepared at >99% purity by a procedure
similar to that described for the bis(tri-n-hexylsiloxy)
derivative (Wheeler et al., 1984).
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DLa-dipalmitoyl-phosphatidylcholine (DPPC) was a pro-
duct of Sigma Chemical Co. All other chemicals and solvents
were analytical grade reagents.
Animals and tumours
Female Balb/c mice (18-20 g body weight) obtained from
Charles River (Como, Italy) were used as the experimental
model. The mice were grown in cages with free access to
standard dietary food and tap water. Animal care was made
according to the guidelines established by the Italian commit-
tee for experiments on animals. The MS-2 fibrosarcoma has
been supplied by Istituto Nazionale dei Tumori, Milan. The
tumour was intramuscularly implanted in the right hind leg
of mice by injection of 0.25 ml of a cell suspension contain-
ing at least 106 cells ml-'. All experiments were started at 8
days after tumour implantation, when tumour diameter was
0.7-0.8 cm and the extent of spontaneous necrosis in the
tumour was negligible. No spontaneous remission of the
tumour was observed. When necessary, the mice were anaes-
thetised by i.p. injection of Ketalar (150mgkg-').
New Zealand rabbits were used for iso-BOSiNc distribu-
tion studies by ultracentrifuge analysis of the serum.
Liposomepreparation
Iso-BOSiNc (0.46mg from a stock solution in tetrahydro-
furan) and DPPC (60 mg) were dissolved in chloroform
(12 ml). The solution was dried under reduced pressure by a
Rotavapor 110. The phospholipid film thus obtained was
suspended in 10 ml PBS with mechanic stirring in the
presence of glass beads.
The suspension was sonicated for 30 min at 50°C, allowed
to spontaneously cool to room temperature and centrifuged
at 3,500-4,000 r.p.m. for 10 min. The surnatant contains
small unilamellar DPPC liposomes with an external diameter
of about 28 nm, as assessed by electron microscopy. Iso-
BOSiNc is incorporated into the liposomal vesicles in a
monomeric form as suggested by the position of the absorp-
tion maximum at 774 nm and the presence of fine structure
in the red absorption region (Figure 1). The absorption
spectrum is coincident with the fluorescence excitation spect-
rum (emission wavelength, 780nm), in agreement with the
fact that aggregated naphthalocyanines have a very low, if
any, fluorescence quantum yeld. The iso-BOSiNc concentra-
tion in the liposome suspension was calculated by absorbance
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at 774 nm using e = 5.57 x 105 M-l cm' in tetrahydrofuran
(W.E. Ford, personal communication).
Pharmacokinetic studies
Thirty tumour-bearing mice were intravenously injected with
two different doses (2 mg kg-' and 0.5 mg kg-') of iso-
BOSiNc incorporated into DPPC liposomes. The mice (three
mice at each time) were killed at 3 h, 12 h, 24 h, 48 h and 1
week after injection and the serum, the tumour and selected
normal tissues (liver, spleen, skin, brain, lung, kidneys and
muscle in the contralateral leg) were quickly removed and
washed with saline. The same tissues were also analysed in
uninjected mice.
It was not possible to follow the pharmacokinetic
behaviour of iso-BOSiNc at times longer than 1 week after
injection since the MS-2 fibrosarcoma shows a substantial
amount of spontaneous necrosis after about 20 days from
transplantation. However, we have followed the phar-
macokinetic behaviour of iso-BOSiNc in selected tissues of
healthy mice at times between 1 and 4 weeks after injection.
In order to extract iso-BOSiNc, about 200mg of tissue
were thoroughly homogenised with a Teflon homogeniser in
a Potter vessel using 2 ml of 2% aqueous SDS. The
homogenate was then diluted with 2 ml of 2% aqueous SDS
and incubated for I h at room temperature under gentle
magnetic stirring. The suspension thus obtained was cent-
rifuged at 3,000 r.p.m. at room temperature for 15 min. A
portion of the surnatant (1 ml) was added to 2 ml of tet-
rahydrofuran. The resulting mixture was centrifuged at
3,000 r.p.m. for 15 min, the surnatant was collected and
analysed by a spectrophotofluorimetric procedure as specified
below. In preliminary experiments, we observed that a second
treatment of the pellet by the same extraction procedure gave
iso-BOSiNc recoveries which were always lower than 5% of
the originally extracted amount.
The serum was isolated from blood by centrifugation at
3,000 r.p.m. for 15 min. Fifty microlitres of the serum was
added to 700pl of 2% aqueous SDS and 1.5 ml of tetrahyd-
rofuran, and the mixture was centrifuged at 3,000 r.p.m. for
15 min after which the surnatant was collected and analysed.
The fluorescence spectrum of the solutions was recorded at
wavelengths above 730 nm (Xe)c = 690 nm). The fluorescence
intensity was then converted into iso-BOSiNc concentration
(JLg of dye per g of tissue or ng of dye per ml of serum) by
interpolation with a calibration plot.
Chromatographic studies
Chromatographic analyses of sera taken at 2 h after adminis-
tration of iso-BOSiNc were obtained from mice injected with
two doses of photosensitiser (0.5 and 2.0 mgkg-'). The
serum was taken 2 h after administration of iso-BOSiNc.
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Figure 1 Typical absorption spectrum of Si-(IV)-naphthalo-
cyanine in an aquoseus dispersion (pH 7.4) of small unilamellar
liposomes of dipalmitoyl-phosphatidylcholine.
Serum samples were chromatographed on a column (1.7 x
140 cm) of Sephacryl S-300, which had been equilibrated
with 0.01 M phosphate buffer at pH 7.4, containing 0.15 M
NaCl. The column was eluted at a flow rate of 31.2 ml h-'
and 2.6ml fractions were collected. The fraction collector
was connected to a 2238 LKB UV-cord and the protein
content was continuously recorded by monitoring the absorb-
ence of the eluate at 280 nm. The collected fractions were
also assayed for 780 nm fluorescence emission exciting at
690 nm.
Discontinuous density gradient ultracentrifugation ofsera
Ultracentrifuge analysis of the distribution of iso-BOSiNc
among the various lipoprotein classes were obtained from
serum of healthy rabbits injected with 0.5 and 1.0 mgkg-'
iso-BOSiNc. The distribution of dyes in rabbit serum is
essentially identical to that observed in mouse serum (Jori,
1985). The serum (15 ml) was taken at 2 h after administra-
tion.
Ultracentrifugation studies were performed at 39,000
r.p.m. with a Kontron apparatus. The density gradient was
obtained by addition of aqueous KBr to the serum. Four
density regions were obtained corresponding to four classes
of proteins: very low density (VLDL, d< 1.006), low density
(LDL, 1.006<d<1.063), high density (HDL, 1.063<d<
1.21) lipoproteins and a fraction at d> 1.21 corresponding to
the other serum proteins (bottom).
The purity of the fractions was assayed by agarose gel-
electrophoresis. The content of proteins, triglycerides, phos-
pholipids and cholesterol was measured in order to calculate
the total lipoprotein mass (holoprotein) (Barel et al., 1986).
The amount of iso-BOSiNc bound with each protein frac-
tion was determined by spectrophotofluorimetric analysis
after extraction of the photosensitiser.
Photodynamic therapy
For experimental PDT studies we have used tumour-bearing
mice injected with 0.5 mg kg-' lipsome-bound iso-BOSiNc.
Phototreatments were performed at 24 h after administration
of the drug. Light from a 250 W halogen lamp (Teclas,
Lugano, Switzerland) was focused into a bundle of optical
fibres having a total diameter of 0.6cm. The fibre tip was
placed at 1 cm from the surface of the tumour. The lamp was
equipped with a set of optical cut-on and cut-off filters which
eliminated all visible and infrared radiation outside the
700-800 nm interval. The development of tumour necrotic
area was measured as a function of time after the end of
PDT. In general the tumour was irradiated at a dose-rate of
180 mW cm-2 (measured at the end of the fibre bundle) and
a total light dose of 450 J cm-2. The extent of tumour necro-
tic area was also measured as a function of the irradiation
dose-rate in order to define the optimal phototherapeutic
parameters. In this case the tumour was irradiated at a total
light dose of 450 J cm-2 and the necrotic area was analysed
at 24 h after the end of PDT. The procedure for measuring
the extent of tumour necrosis involved the fixation of the
tumour in 10% formalin, followed by sectioning the tumour
at 2 mm intervals. The width and depth of the necrotic area
were measured for each tissue slice. The maximum values of
width and depth were recorded for each tumour and their
product was used as a quantitative evaluation of the tumour
response (Reddi et al., 1990). Each point reported in Figures
4 and 5 represents the mean (± s.d.) from three animals.
Results
Pharmacokinetic studies
The recovery of iso-BOSiNc from tumour, serum and select-
ed normal tissues at different times after injection of 2mg
kg-' is reported in Table I. The data represent the average of
recoveries from at least three different mice, the largest devia-968 V. CUOMO et al.
tion from the reported values being 15%. The clearance of
the drug from the serum follows biphasic kinetics; about
90% of photosensitiser is eliminated during the initial 24 h.
Significant concentrations of photosensitiser, of the order of
gsg per g of tissue, are accumulated and retained by the
tumour. On the other hand, the peritumoral tissue (i.e.
muscle) accumulates significantly smaller amounts of iso-
BOSiNc and the ratio of iso-BOSiNc concentration in
TableI Recoveries ofiso-BOSiNc from tumour-bearing BALB/cmice
injected with 2 mg kg-' of dye
Time lapse after injection
3h 12h 24h 48h 1 week
Serum 8060.01 1196.51 639.39 159.32 5.21
Tumour 0.97 1.74 1.20 1.25 0.32
Muscle 0.12 0.10 0.19 0.04 0.03
Liver 6.99 5.99 12.03 13.96 7.39
Skin 0.16 0.12 0.18 0.20 0.30
Brain 0.08 0.02 0.01 0.00 0.00
Lung 1.04 0.35 0.28 0.28 0.28
Spleen 5.79 5.38 1.82 3.47 1.38
Kidney 1.19 0.48 0.65 0.63 0.51
Data expressed as ;Lg of iso-BOSiNc per g of tissue or ng of
iso-BOSiNc per ml of serum (average of three mice).
Table II Recoveries of iso-BOSiNc from tumour-bearing BALB/c
mice injected with 0.5 mg kg-' of dye
Time lapse after injection
3h 12h 24h 48h 1 week
Serum 1731.29 354.91 196.21 23.08 0.00
Tumour 0.28 0.30 0.34 0.11 0.09
Muscle 0.11 0.04 0.02 0.00 0.00
Liver 4.09 4.81 3.61 5.94 1.78
Skin 0.01 0.02 0.02 0.01 0.03
Spleen 0.76 1.40 1.40 0.94 0.57
Data expressed as fig of iso-BOSiNc per g of tissue or ng of
iso-BOSiNc per ml of serum (average of three mice).
tumour and muscle ranges between 10 and 20. Unusually
large amounts of iso-BOSiNc are recovered in the liver and
spleen and they are present even at I week after administra-
tion. Pharmacokinetic studies with normal mice show that
large concentrations of iso-BOSiNc are recovered from liver
and spleen also at 4 weeks after injection of 2 mg kg-' (Table
III). Moreover, the iso-BOSiNc concentration in the skin
shows a tendency to increase at long times after injection.
This fact may be related with the prolonged retention of
liposome-associated drugs by serum high-density lipoproteins
(Jori, 1987), which could release iso-BOSiNc to cutaneous
districts.
At a lower injected dose of photosensitiser (0.5 mgkg-')
we find again a high ratio of iso-BOSiNc concentration in the
tumour and muscle (Table II). However, the amounts of
drug taken up by the liver and spleen is substantially reduced
and a gradual elimination of iso-BOSiNc from these tissues
can be observed. Similar pharmacokinetic data are obtained
for normal mice injected with 0.5 mg kg-': as shown in Table
III the photosensitiser is slowly eliminated from the liver
while there are similar concentrations of iso-BOSiNc in the
spleen at times between 1 and 4 weeks after injection.
Chromatographic and ultracentrifuge studies
The chromatograms of the serum obtained from mice
injected with 2.0 mg kg-' and 0.5 mgkg-' iso-BOSiNc are
shown in Figures 2 and 3, respectively. For serum proteins
the absorbence peak 'A' represents an unidentified high
c
0
Table III Recoveries of iso-BOSiNc from healthy mice injected with
2.0 or 0.5 mg kg-' ofdye
Injected dose Time lapse after injection
Tissue (mgkg-1) 1 week 2 weeks 4 weeks
Serum 2 n.d. 13.54 0.00
Skin 2 n.d. 0.21 0.12
Liver 2 9.55 10.55 8.42
Spleen 2 7.22 9.87 8.94
Serum 0.5 0.00 0.00 0.00
Skin 0.5 0.04 0.04 0.02
Liver 0.5 5.27 4.87 2.67
Spleen 0.5 2.93 3.09 3.65
Data expressed as yg of iso-BOSiNc per g of tissue or ng of
iso-BOSiNc per ml of serum (average of three mice). n.d.: not
determined.
Table IV Distribution of iso-BOSiNc among the various lipoprotein
classesoftheserum ofhealthyrabbitsinjectedwith0.5or 1.0 mg kg-' of
dye
Injected dose iso-BOSiNc/ iso-BOSiNc/
Protein (mgkg-') % iso-BOSiNc apoprotein holoprotein
VLDL 0.5 2.63 239.61 71.50
1.0 2.39 550.65 217.08
LDL 0.5 57.79 5079.44 1231.54
1.0 48.01 5770.06 1094.50
HDL 0.5 35.68 485.35 396.40
1.0 48.05 4856.78 2401.10
Bottom 0.5 3.89 3.96 3.92
1.0 1.55 3.18 3.13
The serum was taken at 2 h after injection. Data expressed as % of
total recovery of iso-BOSiNc or ng of iso-BOSiNc per mg of protein.
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Figure 2 Chromatogram of the serum of BALB/c mice 2 h after
the administration of liposomal iso-BOSiNc at a dose of
2 mg kg-'. The chromatogram shows the absorbence at 280 nm
(*---0) and the fluorescence emission at 780 nm (A----A).
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Figure 3 Chromatogram of the serum of BALB/c mice 2 h after
the administration of liposomal iso-BOSiNc at a dose of
0.5 mg kg-'. The chromatogram shows the absorbence at 280 nm
(0---0) and the fluorescence emission at 780 nm (A- - -A).NAPHTHALOCYANINES IN PHOTODYNAMIC THERAPY 969
molecular weight class of proteins, the peak 'B' represents the
lipoproteins and the peak 'C' represents mainly albumin and
globulins (Barel et al., 1986). Clearly, the dye is distributed
among all serum proteins, although the fraction associated
with peak 'A' is substantially reduced upon injection of
0.5 mg kg-'. In all cases, the absorption and fluorescence
properties of iso-BOSiNc in the different fractions were
typical of the monomeric dye.
The results of ultracentrifuge analysis of the distribution of
iso-BOSiNc among the various lipoprotein classes are shown
in Table IV.
Phototherapy studies
Our PDT protocol causes the appearance of tumour necrosis
within about 12 h from the end of phototreatment. On the
other hand, no appreciable photodamage (e.g. oedema,
erythema or ulceration) is observed in the skin overlying or
adjacent to the tumour.
Figure 4 shows the extent of tumour necrotic area as a
function of time after the end of PDT. The necrotic area
reaches a maximum level (total necrosis) at about 24 h after
the end of PDT. In Figure 5 we show the extent of tumour
necrosis as a function of the irradiation dose rate. Appar-
ently, tumour necrosis increases with increasing dose-rate; in
particular, the necrotic area and dose rate (in the range
between 100 mWcm-2 and 180mWcm-2) seem to be
linearly correlated.
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Figure 4 Development of tumour necrosis as a function of time
after PDT of MS-2 fibrosarcoma. PDT was performed at 24 h
after injection of 0.5 mg kg-' iso-BOSiNc. Irradiation dose-rate
was 180 mW cm-2, total light dose was 450 J cm-2
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Figure 5 Effect of irradiation dose-rate on the extent of the
necrotic area obtained by PDT of MS-2 fibrosarcoma at 24h
after injection of 0.5 mg kg-' iso-BOSiNc. Total light dose was
450Jcm I. The necrosis was measured at 24h after the end of
PDT.
Discussion
Our pharmacokinetic data show that significant concentra-
tions of iso-BOSiNc are accumulated and slowly eliminated
by our tumour model. On the other hand, the muscle
accumulates very small amounts ofiso-BOSiNc, so that quite large tumour/muscle ratios of photosensitiser concentration
are found. This fact should guarantee a safe phototherapeutic
index, at least in our tumour model, namely a minimal risk
of photodamage to tumour-adjacent tissues. At the same
time, low iso-BOSiNc amounts are recovered from the skin,
which should minimise the risk of cutaneous photosensitivity.
No significant amounts of iso-BOSiNc are recovered from
brain, in agreement with the reported inability of polycyclic
aromatic compounds to cross the blood-brain barrier (Zhou,
1989). As a consequence, iso-BOSiNc should not induce toxic
effects at the level of the central nervous system. The very
small amounts of drug accumulated by kidneys suggest that
iso-BOSiNc (as other photosensitisers) is mostly eliminated
from the organism via the bile-gut pathway (Reddi et al.,
1987). Actually, large amounts of the drug are present in the
liver and in the spleen even at one week after administration
of 2mgkg-1 iso-BOSiNc. The prolonged retention of this
photosensitiser by the main components of the reticuloendo-
thelial system is further confirmed by our pharmacokinetic
studies with normal mice. On the other hand, we observe a
faster kinetics of iso-BOSiNc elimination by the liver and the
spleen after injection of a lower dose (0.5mgkg-').
This fact is possibly connected with the effect of injected
dose on the distribution of the photosensitiser among the
serum proteins: the chromatographic and ultracentrifuge
analyses of sera obtained from mice and rabbits injected with
iso-BOSiNc doses in the range 0.5-2.0 mg kg-' indicate that
the drug is mainly transported by the LDL at the lower
injected doses, while iso-BOSiNc is largely associated with
other proteins at the higher doses.
As known, HDL are responsible for transport and clear-
ance of cholesterol from the components of the reticuloendo-
thelial system. Therefore, maximum selectivity of tumour
targeting by iso-BOSiNc is obtained by injection of 0.5 mg
kg-' drug. Actually, the ultracentrifuge analysis of the dist-
ribution of iso-BOSiNc among the different classes of lipo-
proteins and other serum proteins shows that only a small
fraction of photosensitiser (3.89%) is recovered in the bottom
fraction in agreement with the results of chromatographic
analysis of the serum after injection of 0.5 mg kg-' iso-
BOSiNc. The largest amount of iso-BOSiNc is associated
with LDL (57.8%) and to a lesser extent (35.7%) with HDL.
This distribution is very significant since LDL represent the
protein class mainly responsible for the release of some
hydrophobic photosensitising agents to tumour tissues
through a mechanism of receptor-mediated endocytosis (Jori,
1987).
PDT experiments show that the irradiation of tumour at
24h after injection of 0.5mgkg-' iso-BOSiNc induces an
extensive necrosis which reaches a maximum level (total nec-
rosis) at about 24h after the end of the phototreatment,
when dose-rates as large as 180mW cm2 are used. In this
connection, the phototherapeutic efficiency of iso-BOSiNc is
comparable with that observed upon injection of the same
tumour model with 0.2mgkg-' Zinc(II)-phthalocyanine or
10 mg kg-' Hp (Cozzani et al., 1984; Reddi et al., 1990). The
observed increase of the photodamaged tumour area upon
increasing the dose-rate probably does not reflect a
significant contribution from thermal damage. Actually
irradiation of tumour tissues in uninjected mice at 180mW
cm-2 caused no detectable damage. Under these experimental
conditions, the increase of tissue temperature above the basal
level (29-30°C) for the anaesthetised mice was not greater
than 5°C, which is lower than that usually considered to
originate hyperthermal effects (Evensen & Moan, 1988).
Henderson and Mayhew (1990) observed a good response of
subcutaneously implanted RIF (radiation induced fibrosar-
coma) in iso-BOSiNc treated mice to light doses (135 J cm2,
75-100mWcm-2) lower than those used in the present
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study. This can be explained by several differences existing
between the two experimental protocols: the tumour type and
location (intramuscolar vs subcutaneous) often cause different
levels of photosensitivity; moreover, the liposomal carriers of
iso-BOSiNc were different, which may result in different
modalities of photosensitiser transport in the serum and
different distribution of the photosensitiser among the tis-
sular compartments (Ginevra et al., 1990). Actually, Hender-
son and Mayhew (1990) found a large extent ofPDT-induced
vascular damage in their tumour animal model, while ultra-
structural studies on tissue specimens taken from the irrad-
iated MS-2 fibrosarcoma demonstrate a highly preferential
direct damage ofmalignant cells (Jori & Cuomo, unpublished
observations).
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